Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956435 | 0.93 | TGFBR1 (0.48) | TGFBR1MAPK14MAPKAPK2DYRK1AHDAC1 | |
| SCHEMBL5956486 | 0.87 | TGFBR1 (0.57) | TGFBR1MAPK14DYRK1AJAK2EGFR | |
| SCHEMBL5956381 | 0.85 | TGFBR1 (0.46) | TGFBR1MAPK14HRH3KDR | |
| SCHEMBL5956375 | 0.81 | TGFBR1 (0.54) | TGFBR1MAPK14EGFRKDR | |
| SCHEMBL5907467 | 0.80 | TGFBR1 (0.54) | TGFBR1MAPK14MAPKAPK2DYRK1AHDAC1 | |
| SCHEMBL5956473 | 0.80 | TGFBR1 (0.48) | TGFBR1MAPK14DYRK1AJAK2EGFR | |
| SCHEMBL5907462 | 0.80 | TGFBR1 (0.55) | TGFBR1MAPK14MAPKAPK2DYRK1AJAK2 | |
| SCHEMBL5919650 | 0.80 | TGFBR1 (0.55) | TGFBR1MAPK14MAPKAPK2DYRK1AHDAC1 | |
| SCHEMBL5956677 | 0.78 | TGFBR1 (0.52) | TGFBR1MAPK14 | |
| SCHEMBL5956439 | 0.78 | TGFBR1 (0.64) | TGFBR1MAPK14DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885MAPKAPK2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.